Compare PRE & JCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRE | JCE |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Trusts Except Educational Religious and Charitable |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.8M | 269.8M |
| IPO Year | N/A | N/A |
| Metric | PRE | JCE |
|---|---|---|
| Price | $19.38 | $15.91 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $32.00 | N/A |
| AVG Volume (30 Days) | ★ 255.5K | 49.7K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.26% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $77,079,000.00 | N/A |
| Revenue This Year | $219.28 | N/A |
| Revenue Next Year | $124.38 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 201.54 | N/A |
| 52 Week Low | $3.10 | $11.64 |
| 52 Week High | $20.89 | $14.28 |
| Indicator | PRE | JCE |
|---|---|---|
| Relative Strength Index (RSI) | 62.69 | 46.72 |
| Support Level | $15.14 | $15.92 |
| Resistance Level | $20.89 | $16.14 |
| Average True Range (ATR) | 1.38 | 0.20 |
| MACD | 0.21 | -0.01 |
| Stochastic Oscillator | 77.70 | 40.35 |
Prenetics Global Ltd is a health sciences company dedicated to advancing consumer health. The consumer initiative is led by IM8, one of the world's fastest-growing supplement brands; Europa, one of the sports distribution companies in the USA; and CircleDNA, a direct-to-consumer DNA testing company. As the first consumer healthcare company to establish a Bitcoin treasury with its initial approximately $20 million Bitcoin purchase and board-approved comprehensive Bitcoin plan of action, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption.
Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.